Seth Quinn

Diagnosed with Synovial Sarcoma in his left knee in November 2020. He was originally diagnosed with a vascular malformation three years earlier and underwent two embolizations in 2018. Seth was part of a radiation clinical trial and underwent five days of radiation using 6 rems per day for a total of 30 rems at UCLA Medical Center, followed by surgery in December 2020 by Dr. Nicholas Bernthal to remove the 3.2 cm tumor with clear margins.

In December 2021, Seth had surgery by Dr. Jane Yanagawa to remove a 9mm lung nodule with clear margins. He then underwent six rounds of AIM chemotherapy, which shrank the remaining nodules, but three months after surgery, the nodules began to grow. He tried Votrient, a targeted therapy, to stabilize the tumor growth. At his two-month scan, the tumors showed growth, so Seth began the C4 Therapy clinical trial at the City of Hope under the care of Dr. Mark Agulnik on March 31, 2023. So far, Seth has only experienced mild dehydration from the drug and no other side effects.

As of December 2024, Seth continues to fight his cancer and is actively involved in fundraising for Synovial Sarcoma research at Children’s Hospital of Philadelphia (CHOP). Seth attends college at Cal Poly in San Luis Obispo, CA. He studies philosophy and is an avid surfer. You can learn more about Seth and his experience at www.FollowingSeth.com.